Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
|Ōtsuka Seiyaku Kabushiki-gaisha|
TOPIX 100 Component
|Founded||1921 (Originally founded), 1964 (Current corporation)|
Number of locations
|Tatsuo Higuchi (President)|
|Revenue||¥ 531.2 billion (2017)|
|¥ 57.0 billion (2017)|
|Owner||Nomura Trust and Banking investment trusts (11.43%)|
and investment trusts managed by other banks
Number of employees
|Parent||Otsuka Holdings Co. Ltd|
OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.
Otsuka Pharmaceutical Co. LTD HoldingsEdit
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.
In July 2018, Otsuka agreed to acquire Visterra for $430 million cash.
Otsuka Holdings Co. Ltd. HoldingsEdit
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.
In July 2018, Otsuka Holdings acquired renal-focused ReCor Medical, Inc.
- Fujita, Junko; Slodkowski, Antoni (December 16, 2010), Nathan Layne (ed.), Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 (Reuters news), Forexyard, forexyard.com, archived from the original on March 4, 2012, retrieved January 15, 2012
- "Tokushima Vortis". Retrieved October 30, 2020.
- "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
- "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. Retrieved 23 April 2018.
- "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
- "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
- "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
- Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
- https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library], Otsuka Pharmaceutical. Retrieved September 21, 2019.
- Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
- UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, zenopa.com, retrieved January 15, 2012
- Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
- Soble, Jonathan. "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". nytimes.com. Retrieved 23 April 2018.
- "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.